How effective is tazetostat? Clinical data and patient feedback

Tazemetostat is a new type of epigenetic regulation drug that belongs to the EZH2 inhibitor class. It is mainly used to treat relapsed or refractory follicular lymphoma (FL; non-Hodgkin lymphoma) and epithelioid sarcoma (ES; soft tissue sarcoma). The mechanism of action is to block the proliferation and survival of tumor cells by inhibitingEZH2 enzyme activity, thereby inhibiting tumor progression. Because EZH2 mutations can lead to abnormal growth of tumor cells, tazerestat has shown certain efficacy against both EZH2 mutant and wild-type follicular lymphoma.

In clinical studies, tazerestat showed good efficacy and tolerability. The U.S. Food and Drug Administration approved the drug for the treatment of patients with relapsed or refractory follicular lymphoma who carry EZH2 mutations and are suitable for patients who have received at least two previous systemic treatment regimens. Clinical trial data show that among patients with EZH2-mutated follicular lymphoma, the objective response rate (ORR) of tazerestat reached 69%, of which 12% of patients achieved complete response (CR) and 57% of patients achieved partial response (PR). In EZH2 wild-type patients, the objective response rate was 35%. This data shows that the drug is more effective in patients with EZH2 mutations.

For patients with epithelioid sarcoma, the clinical data of tazerestat also has certain value. In a study of 62 patients with metastatic or locally advanced epithelioid sarcoma, tazerestat had an objective response rate of 15%, including 1 complete response and 8 partial responses. Although the overall response rate is relatively low, the drug still provides a new treatment option for this rare tumor.

In terms of safety, tazerestat is generally well tolerated, and adverse reactions mainly include fatigue, nausea, decreased appetite, anemia, and thrombocytopenia. Therefore, the drug is relatively safe, but patients' hematological indicators and liver function still need to be closely monitored. In real-world data analysis, some patients reported that tazerestat has a good effect in controlling tumor progression, especially patients with EZH2-mutated follicular lymphoma who have a higher response rate.

Reference materials:https://www.tazverik.com/